<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888224</url>
  </required_header>
  <id_info>
    <org_study_id>618-10</org_study_id>
    <nct_id>NCT01888224</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With Amnesteem Capsules 40 mg of Mylan Pharmaceuticals Inc., in Healthy, Adult, Male Human Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterise the pharmacokinetic profile of sponsor's test formulation Isotretinoin
      Capsules 40 mg in comparison to the reference formulation Amnesteem (Containing Isotretinoin)
      Capsules 40 mg after single oral dose administration to healthy, normal, adult, human male
      subjects under fed condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two sequence, single dose,
      crossover, oral bioequivalence study of Isotretinoin Capsules 40 mg under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose (0) and 0.5, 1,1.5,2,2.5,3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8,10,12,16,20,24, 36, 48,72 and 96 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Isotretinoin capsules, 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMNESTEEM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Isotretinoin Capsules,40 mg</description>
    <arm_group_label>Isotretinoin capsules, 40 mg</arm_group_label>
    <arm_group_label>AMNESTEEM</arm_group_label>
    <other_name>AMNESTEEM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult human male volunteers between 18 to 45 years of age (both inclusive)
             living in and around Ahmedabad city or western part of India.

          -  Having a Body Mass Index (BMI) between 18.5-27.5 (both inclusive), calculated as
             weight in kg / height in meter2.

          -  Not having any significant disease in medical history or clinically significant
             abnormal findings during screening, medical history, physical examination,laboratory
             evaluations, 12- lead ECG and X-ray chest recordings.

          -  Able to understand and comply with the study procedures, in the opinion of the
             principal investigator.

          -  Able to comply to use 2 forms of effective contraception methods simultaneously during
             Isotretinoin study, and for 1 month after study.

          -  Able to give voluntary written informed consent for participation in the trial.

          -  Able to read and/or understand drug medication Guide either in English or in a
             provided translation when given along with informed consent form.

        Exclusion Criteria

          -  Known hypersensitivity or idiosyncratic reaction to Isotretinoin or any of the
             excipients including parabens or any related drug.

          -  History or presence of any disease or condition which might compromise the
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,
             immunological, dermatological, gastrointestinal or any other body system.

          -  Ingestion of any medicine including herbal medicines at any time within 14 days before
             dosing in Period I. In any such case subject selection will be at the discretion of
             the Principal Investigator.

          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or
             NSAID induced urticaria.

          -  Use of any recreational drugs or history of drug addiction or testing positive in
             prestudy drug scans.

          -  A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol
             consumption of more than 14 standard drinks per week (A standard drink is defined as
             360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as
             rum,whisky, brandy etc) or consumption of alcohol or alcoholic products within 48
             hours prior to receiving study medicine.

          -  Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from
             smoking during the study.

          -  The presence of clinically significant abnormal laboratory values during screening.

          -  History or presence of psychiatric disorders.

          -  A history of difficulty in donating blood.

          -  Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal
             product or participation in a drug research study within a period of 90 days prior to
             the first dose of study medication. Elimination half-life of the study drug should be
             taken into consideration for inclusion of the subject in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Alpeshkumar Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd.,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

